Boehringer Ingelheim advances SIRP immune-oncology program Boehringer Ingelheim advances SIRP immune-oncology program Boehringer and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371
Breakthrough Phase 2 survodutide data liver fibrosis MASH Breakthrough Phase 2 survodutide data liver fibrosis MASH Boehringer Ingelheim’s survodutide shows breakthrough improvement in liver fibrosis with no worsening of MASH in 64.5% of patients with F2 and F3 fibrosis
Spesolimab Phase II data Spesolimab Phase II data New data published in NEJM shows spesolimab improved signs & symptoms of GPP flares
Spesolimab meets key endpoint for GPP flare prevention Spesolimab meets key endpoint for GPP flare prevention Spesolimab meets primary and key secondary endpoint for prevention of generalized pustular psoriasis flares